CalciMedica, Inc.
CALC
NASDAQ·Healthcare·Biotechnology·Mkt cap $4.8M
$1.54
▼ -3.75%
P/E
-1.14
Mkt Cap
$4.8M
52-Wk Range
$1.54–$36.00
52-Week Range
$1.54 - $36.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 90.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary CRAC channel inhibitor technology platform
- First-mover advantage in calcium signaling modulation for inflammation
- Multi-indication potential for single lead candidate
- Experienced management team in immunology and inflammatory disease
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Clinical trial progression and FDA approval pathway for Auxora
Value
Valuation data unavailable
Momentum
Falling
-68.8% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying CALC right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 11, 2026
Reported EPS of -$0.45 vs -$0.29 consensus (-57.9% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-57.9%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
2 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
—
Latest: Guggenheim · Aug 20, 2026
vs Industry
How CALC stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related